PHOTONICSYS LTD

Their core work

PHOTONICSYS is an Israeli photonics engineering SME specializing in optical biosensing instruments, with demonstrated expertise in Surface Plasmon Resonance (SPR) technology for portable, field-deployable diagnostics. Their core contribution to EU consortia is translating optical detection science into compact, real-world instruments — bridging the gap between laboratory-grade photonics and point-of-care testing. In practice, this means building the optical hardware that enables rapid pathogen identification in clinical, food safety, and environmental settings without requiring centralized lab infrastructure. Their name and project portfolio consistently point to photonic systems as the commercial product, not research outputs.

What they specialise in

How they've shifted over time

Both H2020 projects started in 2020, so this is a topic-shift analysis rather than a genuine multi-year timeline. IPANEMA represents a broad, platform-level approach — microfluidics, isothermal amplification, agrifood, environmental monitoring, cyanobacteria — suggesting a versatile biosensor contributor working across multiple application verticals simultaneously. CorDial-S marks a sharp pivot to a single high-urgency application: portable SPR-based COVID-19 diagnostics using nanobodies and magnetic beads, a far more focused and commercially specific project. The shift from wide environmental/agrifood sensing to targeted infectious disease diagnostics likely reflects both a pandemic-driven opportunity and a maturation toward PHOTONICSYS's photonics core competency.

PHOTONICSYS appears to be moving toward portable optical diagnostics for infectious disease — a commercially high-value niche where their SPR hardware expertise and nanobody-detection capability give them a differentiated position likely to attract post-pandemic respiratory and pandemic-preparedness consortia.

How they like to work

PHOTONICSYS has participated exclusively as a consortium member across both projects, never taking a coordinator role — a pattern consistent with a specialized component supplier rather than a project integrator. Despite only two projects, they accumulated 25 unique partners across 13 countries, which indicates they are sought-after contributors embedded in large, multi-disciplinary consortia rather than forming tight bilateral partnerships. This profile suggests they are straightforward to bring into a consortium as a technical hardware provider, but should not be expected to lead administrative or scientific coordination.

From just two projects, PHOTONICSYS built a network of 25 partners across 13 countries — unusually wide for such a small portfolio, indicating their photonics expertise is in demand across diverse European research groups. As an Israeli company, they also bring non-EU geographic diversity that can strengthen consortium eligibility under Horizon rules.

What sets them apart

Among biosensor consortia dominated by molecular biologists, microfluidics engineers, and clinical partners, PHOTONICSYS fills a specific and often hard-to-find niche: photonic instrumentation expertise, particularly SPR, delivered in compact, portable form factors. Their Israel base makes them a non-EU partner with full Horizon eligibility — useful for consortia needing to demonstrate international reach. For a consortium building a point-of-care diagnostic platform, they are a rare find: a private company that can own the optical hardware layer end-to-end.

Highlights from their portfolio

• CorDial-S
  The largest grant (EUR 350,962) and the most commercially direct project — a portable SPR COVID-19 test using nanobodies, directly aligned with PHOTONICSYS's photonics product identity and a clear proof-of-concept for their diagnostic instrument capabilities.
• IPANEMA
  A long-running (2020-2025) Innovation Action spanning agrifood, environmental monitoring, and clinical biosensing — unusual breadth that positions PHOTONICSYS as a cross-sector photonic sensing contributor beyond health alone.